Search

Your search keyword '"Zargar H"' showing total 292 results
Start Over Author "Zargar H"
292 results on '"Zargar H"'

1. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Author

Vasdev, N., Zargar, H., Noël, J. P., Veeratterapillay, R., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L. M., Cookson, M. S., Jacobsen, N. E., Gandhi, N. M., Griffin, J., Montgomery, J. S., Yu, E. Y., Xylinas, E., Campain, N. J., Kassouf, W., Dall’Era, M. A., Seah, J. A., Ercole, C. E., Horenblas, S., Sridhar, S. S., McGrath, J. S., Aning, J., Shariat, S. F., Wright, J. L., Morgan, T. M., Bivalacqua, T. J., North, S., Barocas, D. A., Lotan, Y., Grivas, P., Stephenson, A. J., Shah, J. B., van Rhijn, B. W., Daneshmand, S., Spiess, P. E., Holzbeierlein, J. M., Thorpe, A., and Black, P. C.

Published
2019
Full Text
View/download PDF

2. Evaluating the diagnostic role of in-bore magnetic resonance imaging guided prostate biopsy: a single-centre study

Author

Furrer, MA, Hong, A, Wetherell, D, Heinze, SB, Simkin, P, Chow, K, Lawrentschuk, N, Zargar, H, Furrer, MA, Hong, A, Wetherell, D, Heinze, SB, Simkin, P, Chow, K, Lawrentschuk, N, and Zargar, H

Abstract

BACKGROUND: To evaluate the role of in-bore MRI-guided biopsy (IB-MRGB) in the diagnosis of clinically significant prostate cancer (csPCa). METHODS: In this tertiary single centre study, a total of 125 consecutive patients receiving IB-MRGB over a three-year period were evaluated, including 73 patients who had prior biopsies and 52 biopsy-naïve patients. We assessed cancer detection rate of patients according to the degree of suspicion based on mpMRI findings. Histopathological data were reviewed by experienced uropathologists. RESULTS: The mpMRI was suspicious for PCa (PI-RADS 4/5) in 77% (96/125) and equivocal (PI-RADS 3) in 23% (29/125). The detection rate for csPCa was 54.2% (52/96) and 20.7% (6/29) for suspicious lesions (PI-RADS 4/5) and equivocal lesions (PI-RADS 3), respectively. In subgroup analysis, patients with previous negative biopsy, overall positive biopsy rate and csPCa detection rate were 48.3% (19/35) and 34.5% (13/35), respectively. In patients on AS, 36/44 (81.8%) and 21/44 (47.8%) had PCa and csPCa respectively. In biopsy-naïve patients 34/52 (65.4%) and 27/52 (51.92%) had PCa and csPCa respectively. Of the patients on AS, 18/44 (41.6%) upgraded from ISUP 1 to ISUP 2 PCa, and 4/44 (9.1%) upgraded from ISUP 1 to ISUP 3 PCa on IB-MRGB. A total of 14 Clavien-Dindo≤2 complications occurred in 14 patients (11.2%) that were directly related to the biopsy. No Clavien-Dindo≥3 complications occurred. CONCLUSION: MRI-targeted biopsy is suitable for assessment of csPCa. Given the favourable complications profile, its use may be considered in both the initial biopsy and re-biopsy settings.

Published
2022

8. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium

Author

Mir, C., primary, Marchioni, M., additional, Zargar, H., additional, Zargar-Shoshtari, K., additional, Fairey, A.S., additional, Mertens, L.S., additional, Dinney, C.P., additional, Krabbe, L., additional, Cookson, M.S., additional, Jacobsen, N., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Xylinas, E., additional, McGrath, J.S., additional, Kassouf, W., additional, Dell’Era, M.A., additional, Sridhar, S.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A.J., additional, Shah, J.B., additional, van Rhijn, B.W., additional, Spiess, P.E., additional, Daneshmand, S., additional, and Black, P.C., additional

Published
2020
Full Text
View/download PDF

9. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: Results of an international consortium

Author

Marchioni, M., primary, Mir, M.C., additional, Zargar, H., additional, Grivas, P., additional, Dall’era, M.A.D., additional, Spiess, P.E.S., additional, Van Rhijn, B.W., additional, Lotan, Y., additional, Bivalacqua, T.J., additional, Holzbeierlein, J.M., additional, Thorpe, A., additional, Yu, E., additional, Shariat, S.F., additional, Kassouf, W., additional, Barocas, D.A., additional, Daneshmand, S., additional, Dinney, C.P., additional, Mcgrath, J.S., additional, Sridhar, S.S., additional, Wright, J., additional, North, S., additional, Stephenson, A.J, additional, Xylinas, E., additional, and Black, P., additional

Published
2020
Full Text
View/download PDF

10. Reply by Authors

Author

Veccia, A., primary, Antonelli, A., additional, Francavilla, S., additional, Porpiglia, F., additional, Simeone, C., additional, Lima, E., additional, Zargar, H., additional, Eun, D., additional, Hampton, L. J., additional, and Autorino, R., additional

Published
2020
Full Text
View/download PDF

11. Editorial Comment: Robotic versus other nephroureterectomy techniques: a systematic review and meta-analysis of over 87,000 cases

Author

Veccia, A., Antonelli, A., Francavilla, S., Simeone, C., Guruli, G., Zargar, H., Perdona, S., Ferro, M., Carrieri, G., Hampton, L. J., Porpiglia, F., and Autorino, R.

Subjects
medicine.medical_specialty, Ureteral Neoplasms, business.industry, Urology, MEDLINE, Robotic Surgical Procedures, Robotics, Nephroureterectomy, Diseases of the genitourinary system. Urology, Meta-analysis, Humans, Medicine, Medical physics, RC870-923, Artificial intelligence, business
Published
2020

16. Robotic-assisted radical cystectomy with intracorporeal urinary diversion versus open: early Australian experience

Author

Chow, K, Zargar, H, Corcoran, NM, Costello, AJ, Peters, JS, Dundee, P, Chow, K, Zargar, H, Corcoran, NM, Costello, AJ, Peters, JS, and Dundee, P

Abstract

BACKGROUND: The aim of this study was to describe our initial Australian single surgeon experience with robotic-assisted radical cystectomy (RARC) and intracorporeal urinary diversion (ICUD) and to compare the outcomes with open radical cystectomy (ORC). METHODS: Between January 2014 and June 2016, consecutive patients diagnosed with muscle invasive and high-risk non-muscle invasive bladder cancer undergoing radical cystectomy were included. Treatment modalities included either RARC with ICUD or ORC. ICUD consisted of either intracorporeal ileal conduit or orthotopic neobladder formation. Prospectively collected perioperative and oncological outcomes were analysed. RESULTS: Twenty-six RARC and 13 ORC were performed. Median operating times were 362 and 240 min for RARC and ORC, respectively (P < 0.001). Estimated blood loss for RARC was 300 mL compared with 500 mL for ORC (P = 0.01). Post-operative haemoglobin drop was less in the RARC cohort (20% versus 24%, P = 0.03). There was no statistical difference in overall 90-day complication rates (81% versus 62%, P = 0.25) and 90-day major complication rates (19% versus 23%, P = 0.67) between the RARC and ORC groups, respectively. Positive surgical margins for RARC were 4% and 8% for ORC (P = 1.0). CONCLUSION: Early results demonstrate that the safe introduction of RARC with ICUD in Australia is potentially feasible without compromising perioperative and oncological outcomes. Future randomized trial with larger numbers will be required for further analysis in the Australian setting.

Published
2018

18. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

Author

Vasdev, N., primary, Zargar, H., additional, Noël, J. P., additional, Veeratterapillay, R., additional, Fairey, A. S., additional, Mertens, L. S., additional, Dinney, C. P., additional, Mir, M. C., additional, Krabbe, L. M., additional, Cookson, M. S., additional, Jacobsen, N. E., additional, Gandhi, N. M., additional, Griffin, J., additional, Montgomery, J. S., additional, Yu, E. Y., additional, Xylinas, E., additional, Campain, N. J., additional, Kassouf, W., additional, Dall’Era, M. A., additional, Seah, J. A., additional, Ercole, C. E., additional, Horenblas, S., additional, Sridhar, S. S., additional, McGrath, J. S., additional, Aning, J., additional, Shariat, S. F., additional, Wright, J. L., additional, Morgan, T. M., additional, Bivalacqua, T. J., additional, North, S., additional, Barocas, D. A., additional, Lotan, Y., additional, Grivas, P., additional, Stephenson, A. J., additional, Shah, J. B., additional, van Rhijn, B. W., additional, Daneshmand, S., additional, Spiess, P. E., additional, Holzbeierlein, J. M., additional, Thorpe, A., additional, and Black, P. C., additional

Published
2018
Full Text
View/download PDF

20. SC287 - Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium

Author

Mir, C., Marchioni, M., Zargar, H., Zargar-Shoshtari, K., Fairey, A.S., Mertens, L.S., Dinney, C.P., Krabbe, L., Cookson, M.S., Jacobsen, N., Griffin, J., Montgomery, J.S., Vasdev, N., Yu, E.Y., Xylinas, E., McGrath, J.S., Kassouf, W., Dell’Era, M.A., Sridhar, S.S., Aning, J., Shariat, S.F., Wright, J.L., Thorpe, A.C., Morgan, T.M., Holzbeierlein, J.M., Bivalacqua, T.J., North, S., Barocas, D.A., Lotan, Y., Grivas, P., Stephenson, A.J., Shah, J.B., van Rhijn, B.W., Spiess, P.E., Daneshmand, S., and Black, P.C.

Published
2020
Full Text
View/download PDF

21. Laparoendoscopic single-site (LESS) vs laparoscopic living-donor nephrectomy: a systematic review and meta-analysis

Author

AUTORINO, Riccardo, Brandao LF, Sankari B, Zargar H, Laydner H, Akça O, DE SIO, Marco, Mirone V, Chueh SC, Kaouk J.H., Autorino, Riccardo, Brandao, Lf, Sankari, B, Zargar, H, Laydner, H, Akça, O, DE SIO, Marco, Mirone, V, Chueh, Sc, and Kaouk, J. H.

Subjects
Treatment Outcome, Operative Time, Living Donors, Humans, Kidney Failure, Chronic, Endoscopy, Laparoscopy, Warm Ischemia, Kidney Transplantation, Nephrectomy, Randomized Controlled Trials as Topic
Abstract

The aim of this study was to provide a systematic review and meta-analysis of reports comparing laparoendoscopic single-site (LESS) living-donor nephrectomy (LDN) vs standard laparoscopic LDN (LLDN). A systematic review of the literature was performed in September 2013 using PubMed, Scopus, Ovid and The Cochrane library databases. Article selection proceeded according to the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria. Weighted mean differences (WMDs) were used to measure continuous variables and odds ratios (ORs) to measure categorical ones. Nine publications meeting eligibility criteria were identified, including 461 LESS LDN and 1006 LLDN cases. There were more left-side cases in the LESS LDN group (96.5% vs 88.6%, P < 0.001). Meta-analysis of extractable data showed that LLDN had a shorter operative time (WMD 15.06 min, 95% confidence interval [CI] 4.9-25.1; P = 0.003), without a significant difference in warm ischaemia time (WMD 0.41 min, 95% CI -0.02 to 0.84; P = 0.06). Estimated blood loss was lower for LESS LDN (WMD -22.09 mL, 95% CI -29.5 to -14.6; P < 0.001); however, this difference was not clinically significant. There was a greater likelihood of conversion for LESS LDN (OR 13.21, 95% CI 4.65-37.53; P < 0.001). Hospital stay was similar (WMD -0.11 days, 95% CI -0.33 to 0.12; P = 0.35), as well as the visual analogue pain score at discharge (WMD -0.31, 95% CI -0.96 to 0.35; P = 0.36), but the analgesic requirement was lower for LESS LDN (WMD -2.58 mg, 95% CI -5.01 to -0.15; P = 0.04). Moreover, there was no difference in the postoperative complication rate (OR 1.00, 95% CI 0.65-1.54; P = 0.99). Renal function of the recipient, as based on creatinine levels at 1 month, showed similar outcomes between groups (WMD 0.10 mg/dL, -0.09 to 0.29; P = 0.29). In conclusion, LESS LDN represents an emerging option for living kidney donation. This procedure offers comparable surgical and early functional outcomes to the conventional LLDN, with a lower analgesic requirement. However, it is more technically challenging than LLDN, as shown by a greater likelihood of conversion. The role of LESS LDN remains to be defined.

Published
2014

24. Technique and outcomes of transperineal prostate biopsy: The Victorian Transperineal Biopsy Collaboration.

Author

Lawrentschuk N., Grummet J., Ong W., Weerakoon M., Van Bruwaene S., Van Den Bergh R., Moon D., Frydenberg M., Murphy D., Huang S., Zargar H., Tjandra D., Lawrentschuk N., Grummet J., Ong W., Weerakoon M., Van Bruwaene S., Van Den Bergh R., Moon D., Frydenberg M., Murphy D., Huang S., Zargar H., and Tjandra D.

Abstract

INTRODUCTION & OBJECTIVES: Transperineal prostate biopsy (TPB) has been proposed as a safer more sensitive method for obtaining prostate gland biopsy. Herein we present our technique and report the outcomes and safety profile of TPB utilising our prospective Victorian Transperineal Biopsy Collaboration (VTBC) database. MATERIAL & METHODS: The VTBC is a multi-institutional registry collecting data prospectively from four contributing institutions across Melbourne, Australia. The database is ethics approved at each institution and data collected is based on the minimum dataset published by the Ginsburg Study Group. We present a video of our technique and retrospectively analyse the outcomes of men undergoing TPB. RESULT(S): Our technique for performing TPB, using the Ginsburg protocol, is demonstrated in this video. A total of 1108 men underwent TPB between June 2010 and June 2015, with 894 having adequate histological data for analysis. The indications for TPB were primary biopsy (44.4%), repeat biopsy in the setting of previous negative TRUS biopsy (19%) and confirmatory biopsy for men on active surveillance (36.6%). The mean cohort age was 63.5 (range 41 - 87) and mean pre-biopsy PSA was 9.05 (range 0.14 - 85). In 397 men undergoing TPB as initial biopsy, 328/397(82.6%) were diagnosed with prostate cancer and 215/397 (54.1%) were diagnosed with Gleason >= 7 disease. In 170 men with a prior negative TRUS biopsy, 51/170 (30%) were found to have prostate cancer and 35/170 (20.5%) were diagnosed with Gleason >= 7 disease. Of 327 patients on active surveillance, 137/327 (43%) were upstaged to Gleason >= 7 disease. Overall 230 (25.7%) men were diagnosed with an anterior tumour. The overall rate of acute urinary retention was 3.2%. Only 3(0.3%) patients in the cohort required hospital admission due to biopsy related infection. CONCLUSION(S): The VTBC is the largest reported database of patients having TPB in Australia and New Zealand. The current results show that TPB is

Published
2016

30. Association of Two Polymorphisms in H2B.W Gene with Azoospermia and Severe Oligozoospermia in An Iranian Population

Author

Haji Ebrahim Zargar, H., Mohseni Meybodi, A., Sabbaghian, M., Shahhoseini, M., Asadpor, U., Sadighi Gilani, M. A., Chehrazi, M., Farhangniya, M., and seyed abolhassan shahzadeh fazeli

Subjects
lcsh:R5-920, Histone, Genetics, Male Infertility, Original Article, Andrology, Polymorphism, lcsh:Medicine (General)
Abstract

Background During spermatogenesis, the H2B family, member W (H2B.W) gene, en- codes a testis specific histone that is co-localized with telomeric sequences and has the potential role to mediate the sperm-specific chromatin remodeling. Previously H2B.W genetic variants were reported to be involved in susceptibility to spermatogenesis im- pairment. In the present study, two single nucleotide polymorphisms (SNPs) in 5΄UTR and exon 1 of H2B.W gene were examined to investigate possible association of these polymorphisms with male infertility in Iranian population. Materials and Methods This case control study was conducted in Royan institute during four-year period (2010–2013). Genetic alteration of two SNPs loci, −9C>T and 368A>G, in H2B.W gene were indicated in 92 infertile men who were divided into two main groups includ- ing azoospermia (n=46) and sever oligozoospermia (n=46), while there was 60 fertile men as control group. Azoosperima was also divided into three sub-groups including sertoli cell only syndrome (SCOS, n=21), complete maturation arrest (CMA, n=17) and hypo spermatogenesis (n=8) according to testicular biopsy. For analysis, polymerase chain reaction-restriction frag- ment length polymorphism (PCR-RFLP) technique was applied. Results The frequency of allele −9T was significantly higher in CMA group than in patients with SCOS (P < 0.05). The haplotype TA (corresponding to simultaneous occur- rence of −9T and 368A) compared with haplotype CA (corresponding to simultaneous occurrence of −9C and 368A) in patients suffering from CMA significantly increased, compared with patients had SCOS (P < 0.05). However, statistical studies indicated that in general, the distribution frequencies of −9C>T and 368A>G had no significant difference between the infertile groups and control (P=0.859 and P=0.812, respectively). Conclusion This investigation showed that SNP −9C>T might be contribute to CMA in azoo- spermic patients and SNP 368A>G had no correlation with male infertility in Iranian population.

Published
2013

32. 650 A multi-institutional analysis of pathological and survival outcomes in patients with clinically node positive urothelial bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy

Author

Zargar-Shoshtari, K., primary, Zargar, H., additional, Fairey, A.S., additional, Mertens, L.S., additional, Dinney, C.P., additional, Mir, M.C., additional, Krabbe, L.M., additional, Cookson, M.S., additional, Jacobsen, N.E., additional, Gandhi, N., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Xylinas, E., additional, Campain, N.J., additional, Kassouf, W., additional, Dall'Era, M.A., additional, Seah, J.A., additional, Ercole, C., additional, Horenblas, S., additional, Sridhar, S., additional, McGrath, J.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Garcia, J.A., additional, Stephenson, A.J., additional, Shah, J.B., additional, Van Rhijn, B.W., additional, Daneshmand, S., additional, Spiess, P.E., additional, and Black, P., additional

Published
2015
Full Text
View/download PDF

33. 737 The interval between diagnosis and radical cystectomy does not impact the outcomes of patients treated with neoadjuvant chemotherapy

Author

Xylinas, E.N., primary, Zargar-Shoshtari, K., additional, Shah, J.B., additional, Zargar, H., additional, Fairey, A.S., additional, Mertens, L.S., additional, Krabbe, L-M., additional, Cookson, M.S., additional, Jacobsen, N-E., additional, Gandhi, N., additional, Mir, M.C., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Campain, N.J., additional, Kassouf, W., additional, Dall'Era, M.A., additional, Seah, J-A., additional, Ercole, C.E., additional, Horenblas, S., additional, Sridhar, S.S., additional, McGrath, J.S., additional, Aning, J., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Garcia, J.A., additional, Stephenson, A.J., additional, Van Rhijn, B.W., additional, Daneshmand, S., additional, Dinney, C.P., additional, Spiess, P.E., additional, Black, P., additional, and Shariat, S.F., additional

Published
2015
Full Text
View/download PDF

34. 735 Nomogram predicting cancer specific mortality (CSM) after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer (BC): Results of an international consortium

Author

Mir, Maresma M.C., primary, Ercole, E., additional, Zargar, H., additional, Espiritu, P.N., additional, Fairey, A.S., additional, Mertens, L.L.S., additional, Dinney, C.P., additional, Krabbe, L.M., additional, Cookson, M.S., additional, Jacobsen, N.E., additional, Gandhi, N.M., additional, Griffin, J., additional, Montgomery, J.S., additional, Vasdev, N., additional, Yu, E.Y., additional, Youseff, D., additional, Xylinas, E., additional, Campain, N.J., additional, Kassouf, W., additional, Dall'Era, M.A., additional, Seah, J.A., additional, Horenblas, S., additional, Sridhar, S.S., additional, McGrath, J.S., additional, Aning, J., additional, Shariat, S.F., additional, Wright, J.L., additional, Thorpe, A.C., additional, Morgan, T.M., additional, Holzbeierlein, J.M., additional, Bivalacqua, T.J., additional, North, S., additional, Barocas, D.A., additional, Lotan, Y., additional, Garcia, J.A., additional, Shah, J.B., additional, Van Rhijn, B.W., additional, Daneshmand, S., additional, Spiess, P.E., additional, Black, P.P.C., additional, and Stephenson, A.J., additional

Published
2015
Full Text
View/download PDF

36. 532 Final pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: Does pT0 predict better survival than pTa/pTis/pT1?

Author

Zargar, H., primary, Zargar-Shoshtari, K., additional, Fairey, A., additional, Mertens, L., additional, Dinney, C., additional, Mir, M., additional, Krabbe, L-M., additional, Cookson, M., additional, Jacobsen, N-E., additional, Gandhi, N., additional, Griffin, J., additional, Montgomery, J., additional, Vasdev, N., additional, Yu, E., additional, Xylinas, E., additional, Campain, N., additional, Kassouf, W., additional, Dall'Era, M., additional, Seah, J-A., additional, Ercole, C., additional, Horenblas, S., additional, Sridhar, S., additional, McGrath, J.S., additional, Aning, J., additional, Shariat, S., additional, Wright, J., additional, Thorpe, A.C., additional, Morgan, T., additional, Holzbeierlein, J., additional, Bivalacqua, T., additional, North, S., additional, Barocas, D., additional, Lotan, Y., additional, Garcia, J., additional, Stephenson, A., additional, Shah, J., additional, Van Rhijn, B., additional, Daneshmand, S., additional, Spiess, P.S., additional, and Black, P., additional

Published
2015
Full Text
View/download PDF

38. PE27: Use of the Satinsky clamp in robotic kidney surgery

Author

Barod, R., primary, Rahbar, H., additional, Larson, J., additional, Zargar, H., additional, Marshall, S., additional, Ball, M., additional, Allaf, M., additional, Kaouk, J., additional, Stifelman, M., additional, Bhayani, S., additional, and Rogers, C., additional

Published
2014
Full Text
View/download PDF

46. Serum sialic acid levels in healthy individuals

Author

Hangloo V, Kaul I, and Zargar H

Subjects
Adult, Male, Adolescent, Reference Values, blood, lcsh:R, Sialic Acids, lcsh:Medicine, Female, N-Acetylneuraminic Acid, Human
Abstract

Serum sialic acid values, estimated by thiobarbituric acid method of Warren as modified by Saifer and Gerstenfeld in 50 normal healthy persons of both sexes are reported. The average values were 68.47 +/- 4.85 mg% and 67.77 +/- 7.87 mg% for males and females respectively and for both sexes the value was 68.12 +/- 6.70 mg%. Age and sex have no influence on sialic acid levels in serum.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results